Company intelligence / Profile preview
EsoCap AG
Basel, Basel-Stadt, Switzerlandesocapbiotech.ch ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Successfully completed the double-blind, randomized, placebo-controlled Phase II ACESO study in eosinophilic esophagitis (EoE). Data showed ESO-101 was safe and well tolerated and improved both histologic and endoscopic outcomes in patients with active eosinophilic esophagitis.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Drug delivery platform technologythin film loaded with drugs (including biologics)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Seeking partnerships with major pharmaceutical firms
Beyond the preview
Go deeper on EsoCap AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EsoCap AG.